Atea Pharmaceuticals, Inc.
AVIR
$3.65
$0.1153.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -29.68% | -84.30% | |||
| Gross Profit | 29.68% | 84.30% | |||
| SG&A Expenses | -4.09% | -29.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.10% | 10.70% | |||
| Operating Income | -6.10% | -10.70% | |||
| Income Before Tax | -8.47% | -2.25% | |||
| Income Tax Expenses | 1.97% | -9.78% | |||
| Earnings from Continuing Operations | -8.43% | -2.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.43% | -2.17% | |||
| EBIT | -6.10% | -10.70% | |||
| EBITDA | -6.12% | -10.73% | |||
| EPS Basic | -10.26% | -1.33% | |||
| Normalized Basic EPS | -10.56% | -14.31% | |||
| EPS Diluted | -10.26% | -1.33% | |||
| Normalized Diluted EPS | -10.56% | -14.31% | |||
| Average Basic Shares Outstanding | -1.66% | 0.82% | |||
| Average Diluted Shares Outstanding | -1.66% | 0.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||